Authors

Latest:

Dr. Thigpen on Ovarian Cancer Drugs Not Approved by FDA

James "Tate" T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses the use of agents in ovarian cancer that are not approved by the FDA.

James Tate T

James Tate Thigpen, MD, University of Mississippi School of Medicine

James Urbanic, MD

Latest:

Dr. Urbanic on the Evolution of Radiation in NSCLC

James Urbanic, MD, associate professor, Radiation Medicine and Applied Sciences, University of California, San Diego, discusses the evolution of radiation therapy in the treatment of patients with oligometastatic non–small cell lung cancer.

James W. Fleshman, Jr., MD

Latest:

Dr. James Fleshman on Minimally Invasive Surgery for Colorectal Cancer

James W. Fleshman Jr, MD, from the Department of Surgery and Internal Medicine at Baylor University Medical Center, discusses the surgical management of colorectal cancer.

James Weitzman, MD

Latest:

Dr. Weitzman on Sequencing Challenges in Myeloma Treatment

James Weitzman, MD, medical oncologist, Emerson Hospital and Waltham Cancer Center of Massachusetts General Cancer Center, discusses sequencing challenges in multiple myeloma treatment.

James Welsh, MD

Latest:

Dr. Welsh on New Understanding of Regulating PD-L1 Expression

James Welsh, MD, associate professor of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses a study that examined the regulation of PD-L1 and how it may open up more treatment options for patients with non-small cell lung cancer.

James Wysock, MD

Latest:

Dr. Wysock on the Role of Cytoreductive Nephrectomy in RCC

James Wysock, MD, chief of the urology service at NYC Health and Hospitals at Bellevue, assistant professor, Department of Urology, NYU Langone’s Perlmutter Cancer Center, discusses the role of cytoreductive nephrectomy in renal cell carcinoma.

James Yang, MD

Latest:

Dr. Yang on Osimertinib as First-Line Therapy for EGFR-Positive NSCLC

James Chih-Hsin Yang, MD, discusses the final safety and efficacy results from 2 phase I expansion cohorts from the phase I/II AURA trial.

Jamie E. Chaft, MD

Latest:

Circling the Latest With ctDNA in Lung Cancer

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, discuss the utility with circulating tumor DNA, intriguing data of which were presented during the 2021 ASCO Annual Meeting.

Jamie E. Chaft, MD, Memorial Sloan Kettering Cancer Center

Jamie Koprivnikar, MD

Latest:

Dr. Koprivnikar Discusses FLT3 Inhibitors in Hematologic Malignancies

Jamie Koprivnikar, MD, medical oncologist, John Theurer Cancer Center, discusses FLT3 inhibitors in the treatment of hematologic malignancies.

Jamie Myers, PhD, RN

Latest:

Jamie Myers Describes the Design of Her CRCI Study

Jamie Myers Describes the Design of Her Chemotherapy-Related Cognitive Impairment Study

Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center

Latest:

The Future of Myeloproliferative Neoplasm Treatment

The panelists conclude their discussion by highlighting investigational agents to look forward to.

Jamile M. Shammo, MD, Rush University Medical Center

Jamile Shammo, MD

Latest:

Taking Trial Data to the Clinic in MPN and CLL From ASH 2023: Drs Rogers, Brown, and Shammo

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Jan A. Burger, MD, PhD

Latest:

Dr. Burger on the Current Landscape of CAR T-Cell Therapy in CLL

Jan A. Burger, MD, PhD, discusses the current landscape of CAR T-cell therapy in chronic lymphocytic leukemia.

Jan Burger, MD, PhD, The University of Texas MD Anderson Cancer Center

Jan Poleszczuk, PhD

Latest:

Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal Effects

The combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.

Jan S. Lewin, PhD

Latest:

The Impact of Lymphedema in Patients With Head and Neck Cancer

Jan S. Lewin, PhD, professor, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the impact of lymphedema in patients with head and neck cancer.